StreetInsider.com News Articles

Form 8-K ADIAL PHARMACEUTICALS, For: Mar 06

Fri, 06 Mar 2026 08:15:00 +0000

si-local-file:///var/storage/secattach/20260306/26122467.html

Form 8-K ADIAL PHARMACEUTICALS, For: Mar 06

Fri, 06 Mar 2026 08:15:00 +0000

si-local-file:///var/storage/secattach/20260306/26122467.html

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Fri, 06 Mar 2026 08:00:00 +0000

GLEN ALLEN, Va., March 06, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2025 fiscal year ended December 31, 2025.

Key Highlights:

Regulatory Progress:
- Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04’s pharmacologic profile and regulatory strategy.
- Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company’s proposed

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Fri, 06 Mar 2026 08:00:00 +0000

Key Highlights:

Regulatory Progress:
- Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04’s pharmacologic profile and regulatory strategy.
- Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company’s proposed

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Fri, 06 Mar 2026 08:00:00 +0000

Key Highlights:

Regulatory Progress:
- Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04’s pharmacologic profile and regulatory strategy.
- Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company’s proposed

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Fri, 06 Mar 2026 08:00:00 +0000

Key Highlights:

Regulatory Progress:
- Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04’s pharmacologic profile and regulatory strategy.
- Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company’s proposed

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Fri, 06 Mar 2026 08:00:00 +0000

Key Highlights:

Regulatory Progress:
- Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04’s pharmacologic profile and regulatory strategy.
- Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company’s proposed

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Fri, 06 Mar 2026 08:00:00 +0000

Key Highlights:

Regulatory Progress:
- Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04’s pharmacologic profile and regulatory strategy.
- Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company’s proposed

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Fri, 06 Mar 2026 08:00:00 +0000

Key Highlights:

Regulatory Progress:
- Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04’s pharmacologic profile and regulatory strategy.
- Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company’s proposed

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Fri, 06 Mar 2026 08:00:00 +0000

Key Highlights:

Regulatory Progress:
- Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04’s pharmacologic profile and regulatory strategy.
- Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company’s proposed

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Fri, 06 Mar 2026 08:00:00 +0000

Key Highlights:

Regulatory Progress:
- Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04’s pharmacologic profile and regulatory strategy.
- Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company’s proposed

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Fri, 06 Mar 2026 08:00:00 +0000

Key Highlights:

Regulatory Progress:
- Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04’s pharmacologic profile and regulatory strategy.
- Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company’s proposed

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Fri, 06 Mar 2026 08:00:00 +0000

Key Highlights:

Regulatory Progress:
- Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04’s pharmacologic profile and regulatory strategy.
- Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company’s proposed

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Fri, 06 Mar 2026 08:00:00 +0000

Key Highlights:

Regulatory Progress:
- Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04’s pharmacologic profile and regulatory strategy.
- Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company’s proposed

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Fri, 06 Mar 2026 08:00:00 +0000

Key Highlights:

Regulatory Progress:
- Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04’s pharmacologic profile and regulatory strategy.
- Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company’s proposed

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Fri, 06 Mar 2026 08:00:00 +0000

Key Highlights:

Regulatory Progress:
- Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04’s pharmacologic profile and regulatory strategy.
- Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company’s proposed

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Fri, 06 Mar 2026 08:00:00 +0000

Key Highlights:

Regulatory Progress:
- Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04’s pharmacologic profile and regulatory strategy.
- Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company’s proposed

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Fri, 06 Mar 2026 08:00:00 +0000

Key Highlights:

Regulatory Progress:
- Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04’s pharmacologic profile and regulatory strategy.
- Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company’s proposed

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Fri, 06 Mar 2026 08:00:00 +0000

Key Highlights:

Regulatory Progress:
- Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04’s pharmacologic profile and regulatory strategy.
- Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company’s proposed

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Fri, 06 Mar 2026 08:00:00 +0000

Key Highlights:

Regulatory Progress:
- Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04’s pharmacologic profile and regulatory strategy.
- Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company’s proposed

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Fri, 06 Mar 2026 08:00:00 +0000

Key Highlights:

Regulatory Progress:
- Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04’s pharmacologic profile and regulatory strategy.
- Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company’s proposed

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Fri, 06 Mar 2026 08:00:00 +0000

Key Highlights:

Regulatory Progress:
- Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04’s pharmacologic profile and regulatory strategy.
- Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company’s proposed

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Fri, 06 Mar 2026 08:00:00 +0000

Key Highlights:

Regulatory Progress:
- Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04’s pharmacologic profile and regulatory strategy.
- Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company’s proposed

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Fri, 06 Mar 2026 08:00:00 +0000

Key Highlights:

Regulatory Progress:
- Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04’s pharmacologic profile and regulatory strategy.
- Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company’s proposed

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Fri, 06 Mar 2026 08:00:00 +0000

Key Highlights:

Regulatory Progress:
- Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04’s pharmacologic profile and regulatory strategy.
- Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company’s proposed